Apellis Pharmaceuticals Inc (NASDAQ: APLS) is -11.16% lower on its value in year-to-date trading and has touched a low of $24.34 and a high of $71.90 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The APLS stock was last observed hovering at around $28.39 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $28.35, the stock is -2.48% and -8.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.61 million and changing -0.14% at the moment leaves the stock -17.79% off its SMA200. APLS registered -58.78% loss for a year compared to 6-month loss of -26.50%.
The stock witnessed a -5.91% gain in the last 1 month and extending the period to 3 months gives it a 7.92%, and is -0.56% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.22% over the week and 3.91% over the month.
Apellis Pharmaceuticals Inc (APLS) has around 706 employees, a market worth around $3.53B and $715.22M in sales. Profit margin for the company is -34.97%. Distance from 52-week low is 16.47% and -60.57% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.69%).
with sales reaching $197.91M over the same period.The EPS is expected to grow by 63.08% this year, but quarterly earnings will post 93.21% year-over-year. Quarterly sales are estimated to grow 35.21% in year-over-year returns.
The shares outstanding are 122.07M, and float is at 103.50M with Short Float at 16.48%.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 16.39 million shares valued at $628.67 million. The investor’s holdings represent 13.2269 of the APLS Shares outstanding. As of 2024-06-30, the second largest holder is ECOR1 CAPITAL, LLC with 11.61 million shares valued at $445.26 million to account for 9.3681 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 11.11 million shares representing 8.9675 and valued at over $426.22 million, while VANGUARD GROUP INC holds 7.9171 of the shares totaling 9.81 million with a market value of $376.29 million.
Apellis Pharmaceuticals Inc (APLS) Insider Activity
The most recent transaction is an insider sale by DeLong Mark Jeffrey, the company’s Chief Business & Strat Officer. SEC filings show that DeLong Mark Jeffrey sold 363 shares of the company’s common stock on Feb 11 ’25 at a price of $28.54 per share for a total of $10360.0. Following the sale, the insider now owns 83945.0 shares.
Still, SEC filings show that on Jan 29 ’25, Watson David O. (General Counsel) disposed off 695 shares at an average price of $29.52 for $20519.0. The insider now directly holds 144,299 shares of Apellis Pharmaceuticals Inc (APLS).
